Assessing Study Drug CFZ533 in Patients with Sj grens Syndrome (TWINSS)
Brief description of study
Purpose of this study to find out if the study drug CFZ533, also referred to as iscalimab, is safe and can help others who have Sjögren’s Syndrome (SjS). SjS is an autoimmune disease in which the body’s defense system attacks moisture-producing glands, causing symptoms of extensive dryness (for example, dry eyes and dry mouth), but which may also involve many organ systems, chronic pain and profound fatigue.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research,Sj grens Syndrome,TWINSS
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or female patient ≥ 18 years of age Classification of Sjögren's Syndrome according to ACR/EULAR 2016 criteria
Updated on
26 Oct 2022.
Study ID: 842571